Indivior still waiting as US court delays Dr Reddy's decision

A US judge has extended a temporary restraining order on Dr Reddy's Laboratories, preventing the US company from launching a rival generic version of Indivior's treatment for opioid addiction prior to a decision on a full injunction.

FTSE 250-listed Indivior earlier this month applied for an injunction against Dr Reddy's to stop it from launching its generic version of Suboxone Film, pending the outcome of the recently filed litigation by the UK company related to its US patent number 9,931,305.

The filing was made after Dr Reddy’s won approval from the US drug regulator to produce a generic version of the sublingual film used to treat opioid addicts.

On Friday, Indivior said Judge McNulty at the US District Court for the District of New Jersey had reserved judgment on Indivior's motion, and has extended Indivior's temporary restraining order for an additional 14 days, giving time for the court to consider Indivior's application and ultimately issue a ruling on the PI.

Indivior said it will not make further statements on this matter until the district court makes its final ruling on the PI.